12,407 results on '"Donepezil"'
Search Results
2. Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
- Author
-
National Institute on Aging (NIA)
- Published
- 2024
3. Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers
- Author
-
Shanghai Minimally Invasive Surgery Center
- Published
- 2024
4. Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
- Published
- 2024
5. To Explore the Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer 's Disease
- Author
-
Yunqiang Li, Chief investigator
- Published
- 2024
6. A Single Dose Escalation Study of HHT201 in Healthy Subjects
- Published
- 2024
7. Donepezil Trial for Motor Recovery in Acute Stroke
- Author
-
International Stem Cell Forum
- Published
- 2024
8. Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study (DONEPEZOX)
- Author
-
Federation Francophone de Cancerologie Digestive
- Published
- 2024
9. Multicenter Evaluation of Memory Remediation After TBI With Donepezil (MEMRI-TBI-D)
- Author
-
Spaulding Rehabilitation Hospital, Albert Einstein Healthcare Network, Indiana University, Craig Hospital, TIRR Memorial Hermann, and David B. Arciniegas, MD, Senior Scientist, Brain Injury Research Center, TIRR Memorial Hermann; Clinical Professor of Psychiatry, Baylor College of Medicine
- Published
- 2024
10. δ in Dementia Clinical Trials (δND)
- Author
-
National Institute on Aging (NIA)
- Published
- 2024
11. Molecular insights into anti-Alzheimer's drugs through predictive modeling using linear regression and QSPR analysis.
- Author
-
Ahmed, Wakeel, Ali, Kashif, Zaman, Shahid, and Raza, Asma
- Subjects
- *
REGRESSION analysis , *ALZHEIMER'S disease , *MOLECULAR connectivity index , *MOLECULAR volume , *PREDICTION models , *DONEPEZIL - Abstract
The purpose of this paper is to discuss the use of topological indices (TIs) to anticipate the physical and biological aspects of innovative drugs used in the treatment of Alzheimer's disease. Degree-based topological indices are generated using edge partitioning to assess the drugs Tacrine, Donepezil, Ravistigmine, Butein, Licochalcone-A and Flavokqwain-A. Furthermore, using linear regression, a quantitative structure–property relationship (QSPR) model is developed to predict the characteristics such as boiling point (BP), flash point (FP), molar volume (MV), molecular weight, complexity and polarizability. The findings show that topological indices have the potential to be used as a tool for drugs discovery and design in the field of Alzheimer's disease treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Donepezil as a safe alternative treatment after maculo‐papular eruption related to rivastigmine in Lewy body disease: a case report and pharmacovigilance data.
- Author
-
Chouchana, Margot, Pinel, Sylvine, Colboc, Hester, Soria, Angele, Buard, Geraldine, Delage, Clément, Bloch, Vanessa, and Lilamand, Matthieu
- Subjects
- *
RIVASTIGMINE , *DONEPEZIL , *PHARMACOLOGY , *LEWY body dementia , *PATIENT safety , *CHOLINESTERASE inhibitors , *HYPERLIPIDEMIA , *HYPERTENSION , *DRUG eruptions , *DIABETES - Abstract
The article describes the case of a 79-year old Caucasian man who was treated with donepezil after developing a pruritic erythematous maculopapular eruption at the application site of rivastigmine transdermal patches, which was used to treat his Lewy body disease. The patient's skin lesions did not regress after antihistaminic treatment with cetirizine. A Naranjo scale assessment showed the high probability of the relation of cutaneous adverse effects with rivastigmine transdermal patches.
- Published
- 2024
- Full Text
- View/download PDF
13. A randomized controlled trial of repetitive transcranial magnetic stimulation plus donepezil vs donepezil alone for mild to moderate cognitive impairment due to small vessel cerebrovascular disease.
- Author
-
Shou, Bijiang, Chen, Xuan, and Hou, Yuli
- Subjects
COGNITION disorders treatment ,DONEPEZIL ,STATISTICAL sampling ,SEVERITY of illness index ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,JUDGMENT sampling ,ORAL drug administration ,FUNCTIONAL status ,LONGITUDINAL method ,COMBINED modality therapy ,NEUROPSYCHOLOGICAL tests ,CEREBROVASCULAR disease ,PSYCHOLOGICAL tests ,COGNITION ,DISEASE complications - Abstract
Objectives: Small vessel cerebrovascular disease (SVCVD) accounts for 35% to 67% of vascular dementias, and may be overlooked by healthcare providers due to its insidious onset. SVCVD involves chronic cerebral ischemia and hypoperfusion, endothelial dysfunction, blood-brain barrier disruption, and interstitial fluid reflux. The purpose of this study was to investigate the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) combined with donepezil hydrochloride compared to donepezil alone in the treatment of mild-to-moderate cognitive impairment in patients with SVCVD. Material and methods: A cohort of 115 individuals with mild-to-moderate cognitive impairment due to SVCVD was purposefully selected and randomized into two groups: a test group and a control group. The test group received a combination of repetitive transcranial magnetic stimulation (rTMS) and oral donepezil hydrochloride (10 mg/day), while the control group received oral donepezil alone (10 mg/day). The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores were evaluated in both groups prior to and following the interventions. Results: Following 6 weeks of treatment, both groups demonstrated enhancement in cognitive function. However, a statistically significant difference was observed between the test group and the control group (p <.05 on both the MMSE and the MOCA), favoring the test group. Conclusions: Compared to donepezil alone, the combination of repetitive transcranial magnetic stimulation (rTMS) and donepezil has a significantly greater effect on enhancing cognitive function among individuals experiencing mild-to-moderate cognitive impairment resulting from SVCVD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.
- Author
-
Nissenkorn, Andreea, Bar, Lior, Ben-Bassat, Ariel, Rothstein, Lynn, Abdelrahim, Hoda, Sokol, Riki, Gabis, Lidia V., and Attali, Bernard
- Subjects
PRIMARY cell culture ,ALZHEIMER'S disease ,AUTISM in children ,PARASYMPATHOMIMETIC agents ,AUTISTIC children - Abstract
Introduction: The KCNQ2/KCNQ3 genes encode the voltage-gated K channel underlying the neuronal M-current, regulating neuronal excitability. Loss-of-function (LoF) variants cause neonatal epilepsy, treatable with the M-current-opener retigabine, which is no longer marketed due to side effects. Gain-of-function (GoF) variants cause developmental encephalopathy and autism that could be amenable to M-current, but such therapies are not clinically available. In this translational project, we investigated whether donepezil, a cholinergic drug used in Alzheimer's, suppresses M currents in vitro and improves cognitive symptoms in patients with GoF variants. Methods: (1) The effect of 1 μM donepezil on the amplitude of the M-current was measured in excitatory and inhibitory neurons of mouse primary cultured hippocampal cells. M-current was measured using the standard deactivation protocol (holding at 0 mV and deactivation at -60 mV) in the voltage-clamp configuration of the whole-cell patch clamp technique. The impact of donepezil was also examined on the spontaneous firing activity of hippocampal neurons in the current-clamp configuration. (2) Four children with autism, aged 2.5-8 years, with the following GoF variants were enrolled: KCNQ2 (p. Arg144Gln) and KCNQ 3 (p.Arg227Gln, p.Arg230Cys). Patients were treated off-label with donepezil 2.5-5 mg/d for 12 months and assessed with: clinical Global Impression of Change (CGI-c), Childhood Autism Rating Scale 2 (CARS-2), Adaptive Behavior Assessment System-II (ABAS-II), and Child Development Inventory (CDI). Results: (1) Application of donepezil for at least 6 min produced a significant inhibition of the M-current with an IC50 of 0.4 μM. At 1 μM, donepezil reduced by 67% the M-current density of excitatory neurons (2.4 ± 0.46 vs. 0.89 ± 0.15 pA/pF, p < 0.05*). In inhibitory neurons, application of 1 μM donepezil produced a lesser inhibition of 59% of the M-current density (1.39 ± 0.43 vs. 0.57 ± 0.21, p > 0.05). Donepezil (1 μM) potently increased by 2.6-fold the spontaneous firing frequency, which was prevented by the muscarinic receptor antagonist atropine (10 μM). (2) The CARS-2 decreased by 3.8 ± 4.9 points (p > 0.05), but in two patients with KCNQ3 variants, the improvement was over the 4.5 clinically relevant threshold. The global clinical change was also clinically significant in these patients (CGI-c = 1). The CDI increased by 65% (p < 0.05*), while the ABASII remained unchanged. Discussion: Donepezil should be repurposed as a novel alternative treatment for GoF variants in KCNQ2/KCNQ3 encephalopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Mechanisms of mitophagy and oxidative stress in cerebral ischemia-reperfusion, vascular dementia, and Alzheimer's disease.
- Author
-
Yujie Lyu, Zhipeng Meng, Yunyun Hu, Bing Jiang, Jiao Yang, Yiqin Chen, Jun Zhou, Mingcheng Li, and Huping Wang
- Subjects
ALZHEIMER'S disease ,TISSUE plasminogen activator ,VASCULAR dementia ,NEUROLOGICAL disorders ,CEREBRAL ischemia ,DONEPEZIL - Abstract
Neurological diseases have consistently represented a significant challenge in both clinical treatment and scientific research. As research has progressed, the significance of mitochondria in the pathogenesis and progression of neurological diseases has become increasingly prominent. Mitochondria serve not only as a source of energy, but also as regulators of cellular growth and death. Both oxidative stress and mitophagy are intimately associated with mitochondria, and there is mounting evidence that mitophagy and oxidative stress exert a pivotal regulatory influence on the pathogenesis of neurological diseases. In recent years, there has been a notable rise in the prevalence of cerebral ischemia/reperfusion injury (CI/RI), vascular dementia (VaD), and Alzheimer's disease (AD), which collectively represent a significant public health concern. Reduced levels of mitophagy have been observed in CI/RI, VaD and AD. The improvement of associated pathology has been demonstrated through the increase of mitophagy levels. CI/RI results in cerebral tissue ischemia and hypoxia, which causes oxidative stress, disruption of the blood-brain barrier (BBB) and damage to the cerebral vasculature. The BBB disruption and cerebral vascular injury may induce or exacerbate VaD to some extent. In addition, inadequate cerebral perfusion due to vascular injury or altered function may exacerbate the accumulation of amyloid β (Aβ) thereby contributing to or exacerbating AD pathology. Intravenous tissue plasminogen activator (tPA; alteplase) and endovascular thrombectomy are effective treatments for stroke. However, there is a narrow window of opportunity for the administration of tPA and thrombectomy, which results in a markedly elevated incidence of disability among patients with CI/RI. It is regrettable that there are currently no there are still no specific drugs for VaD and AD. Despite the availability of the U.S. Food and Drug Administration (FDA)-approved clinical first-line drugs for AD, including memantine, donepezil hydrochloride, and galantamine, these agents do not fundamentally block the pathological process of AD. In this paper, we undertake a review of the mechanisms of mitophagy and oxidative stress in neurological disorders, a summary of the clinical trials conducted in recent years, and a proposal for a new strategy for targeted treatment of neurological disorders based on both mitophagy and oxidative stress. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Relationship between the response to donepezil and plasma amyloid beta oligomers in patients with Alzheimer's disease.
- Author
-
Yang, YoungSoon, Huh, Kyoon, and Kwak, Yong Tae
- Subjects
- *
ALZHEIMER'S disease , *ALZHEIMER'S patients , *BIOMARKERS , *BARTHEL Index , *DONEPEZIL - Abstract
Aim Methods Results Conclusions To date, there is no reported effective biomarker that can predict which Alzheimer's disease (AD) patients will respond to donepezil and which will not. This study aimed to investigate whether baseline values of Aβ oligomers (AβOs), measured by the Multimer Detection System‐Oligomeric Aβ (MDS‐OAβ), can be used to predict responders after 6 months of donepezil medication.The study enrolled 104 patients diagnosed with probable AD. After 6 months of donepezil medication, the response to treatment was evaluated by re‐assessing the Korean version of the Mini‐Mental State Examination (K‐MMSE) and Clinical Dementia Rating scale‐Sum of Box (CDR‐SB) scales conducted at baseline. The patients were categorized into two groups according to the baseline MDS‐OAβ values known as the cut‐off for AD diagnosis: a group with values below 0.78 and another group with values equal to or above 0.78.After 6 months of medication, the number of responders was 50 (49.5%). Responders exhibited significantly worse baseline CDR, CDR‐SB, K‐MMSE, and Barthel index compared with non‐responders. There was a significantly higher number of responders among patients with MDS‐OAβ values below the cut‐off of 0.78 compared with those with values equal to or above this threshold. Furthermore, there was a significant improvement in the K‐MMSE and CDR‐SB after 6 months of donepezil medication in patients with MDS‐OAβ values below 0.78 compared with those with values equal to or above 0.78.Baseline MDS‐OAβ values might constitute a novel biochemical marker for the efficacy of 6 months of donepezil treatment in AD.
Geriatr Gerontol Int 2024; ••: ••–•• . [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. Oral Chinese herbal medicine combined with donepezil for mild cognitive impairment: A systematic review and meta‐analysis.
- Author
-
Liu, Lingling, Zhang, Claire Shuiqing, Zhang, Anthony Lin, Cai, Yefeng, and Xue, Charlie Changli
- Subjects
- *
MONTREAL Cognitive Assessment , *MILD cognitive impairment , *HERBAL medicine , *CHINESE medicine , *COGNITIVE ability - Abstract
Background Methods Results Conclusions This study aims to evaluate the add‐on effects of oral Chinese herbal medicine (CHM) for mild cognitive impairment (MCI), when used in addition to donepezil compared to donepezil alone.Randomized controlled trials comparing these treatments across all types of MCI were identified from nine databases and three registers until August 2023. Outcome measures were Mini‐Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and adverse events (AEs). Methodological quality was assessed using Cochrane risk‐of‐bias tool, and evidence certainty was evaluated using the GRADE method.Involving 1611 participants across 20 studies, meta‐analysis results indicate that oral CHM combined with donepezil significantly improved cognitive function in MCI patients compared to donepezil alone, as evidenced by MMSE (1.88 [1.52, 2.24], I2 = 41%, 12 studies, 993 participants) and MoCA (MD: 2.01 [1.57, 2.44], I2 = 52%, 11 studies, 854 participants). Eleven studies reported details of AEs, identifying gastrointestinal symptoms and insomnia as the most common symptoms. No significant difference in AEs frequency was found between the groups (RR: 0.91 [0.59, 1.39], I2 = 4%, 11 studies, 808 participants). All 20 studies were evaluated as having “some concerns” regarding the overall risk of bias. The certainty of evidence for MMSE was “moderate” and “low” for MoCA. From frequently utilized herbs, two classical CHM formulae were identified: Kai xin san and Si wu decoction. The observed treatment effects of commonly used herbs may be exerted through multiple pharmacological mechanisms, including anti‐inflammatory, anti‐oxidative stress, anti‐apoptotic actions, promotion of neuronal survival and modulation of the cholinergic system.The concurrent use of oral CHM and donepezil appears to be more effective than donepezil alone in improving the cognitive function of MCI, without leading to an increase in AEs. While recognizing concerns of overall methodological quality, this combined therapy should be considered as an alternative option for clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis.
- Author
-
Sheikh, Mehak and Ammar, Mohammad
- Subjects
ALZHEIMER'S disease ,VASCULAR dementia ,COGNITIVE ability ,DEMENTIA patients ,COGNITION disorders - Abstract
Objective: The purpose of this study was to compare donepezil at 5 mg and 10 mg/day against a placebo to systematically evaluate its effectiveness in improving cognitive function among patients suffering from dementia at any stage. Method: For this systematic review and meta-analysis, we looked up Medline, Scopus, Embase, Web of Science, and The Cochrane Library for articles on the efficacy of donepezil in dementia published in the past 20 years and summarized the placebo and intervention data. Initially, a total of 2,272 articles were extracted using our search query and after the inclusion and exclusion criteria set for extraction of data, 18 studies were included in this review using PRISMA flowchart. The ADAS-cog and MMSE assessment scales were used for measuring the outcomes using IBM SPSS 29.0 for the meta-analysis. Result: The meta-analysis comprised a total of 18 RCTs (randomized controlled trials) that were randomized to receive either donepezil 5 mg/day (n = 1,556), 10 mg/day (n = 2050) or placebo (n = 2,342). Meta-analysis concerning efficacy showed that donepezil at 10 mg/day significantly improved the MMSE score (g: 2.27, 95%CI: 1.25-3.29) but could not substantially reduce the ADAS-cog. At 5 mg/day donepezil, an overall slight improvement in MMSE score (Hedges' g: 2.09, 95%CI: 0.88-3.30) was observed. Conclusion: Both donepezil 5 mg/day and 10 mg/day doses demonstrated improved cognitive functions for patients with dementia, however results indicated that the 10 mg/day dose was more efficacious. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies.
- Author
-
Matsumoto, Shoya, Yakabe, Mitsutaka, Hosoi, Tatsuya, Fujimori, Kenji, Tamaki, Junko, Nakatoh, Shunichi, Ishii, Shigeyuki, Okimoto, Nobukazu, Akishita, Masahiro, Iki, Masayuki, and Ogawa, Sumito
- Subjects
- *
DONEPEZIL , *RISK assessment , *PEARSON correlation (Statistics) , *LEWY body dementia , *HIP fractures , *BONE density , *HEALTH insurance reimbursement , *RESEARCH funding , *SEX distribution , *AGE distribution , *VERTEBRAL fractures , *DESCRIPTIVE statistics , *CHI-squared test , *BONE fractures , *NOOTROPIC agents , *DEMENTIA , *OSTEOPOROSIS , *COMPARATIVE studies , *CONFIDENCE intervals , *DATA analysis software , *DEMENTIA patients , *ACCIDENTAL falls , *COGNITION , *TIME , *DISEASE risk factors , *OLD age - Abstract
Aim: Patients with dementia with Lewy bodies (DLB) are at a high risk for falls and fractures. Although cholinesterase inhibitors reportedly are effective in suppressing the progression of cognitive symptoms in DLB patients, their effects on fracture risk remain unclarified. This study aimed to evaluate the association between donepezil use and hip fracture risk in older patients with DLB. Methods: Using the Japanese insurance claim database, we collected the data of patients aged ≥65 years with DLB from April 2012 to March 2019. After propensity score matching, we compared the fracture rate over 3 years between DLB patients receiving donepezil and those not receiving antidementia drugs. Results: Altogether, 24 022 239 individuals aged ≥65 years were newly registered from April 2012 to March 2016 and had verifiable information from 6 months before to 3 years after the registration. We identified 6634 pure‐DLB patients and analyzed the data of 1182 propensity score‐matched pairs. The characteristics, including age, sex, fracture history, osteoporosis, and bone mineral density test rate, of the two groups were well balanced by propensity score matching. The incidence rate of hip fracture was significantly lower in DLB patients receiving donepezil than in those not receiving antidementia drugs (0.60 vs. 1.44/100 person‐years, P < 0.001), whereas that of vertebral fractures was the same. Conclusions: Donepezil administration in Japanese people aged ≥65 years with DLB was significantly associated with a decreased risk of hip fracture. Donepezil may provide new benefits to DLB patients. Geriatr Gerontol Int 2024; 24: 782–788. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis.
- Author
-
Nham, Tina, Garcia, Michael Cristian, Tsang, Kai La Jennifer, Silva, Jessyca Matos, Schneider, Tyler, Deng, Jiawen, Lohit, Simran, Mbuagbaw, Lawrence, and Holbrook, Anne
- Subjects
- *
DONEPEZIL , *MEDICAL information storage & retrieval systems , *MORTALITY , *DRUG side effects , *ALZHEIMER'S disease , *CARDIOVASCULAR diseases , *ACADEMIC medical centers , *DATA analysis , *RESEARCH funding , *MAJOR adverse cardiovascular events , *SYNCOPE , *META-analysis , *DESCRIPTIVE statistics , *TREATMENT duration , *SYSTEMATIC reviews , *CLASSIFICATION , *MEDLINE , *VENTRICULAR tachycardia , *ELECTROCARDIOGRAPHY , *DISEASES , *ODDS ratio , *MEDICAL databases , *SEIZURES (Medicine) , *CARDIAC arrest , *CONFIDENCE intervals , *DATA analysis software , *PROARRHYTHMIA , *PATIENT aftercare , *DISEASE complications - Abstract
Background: Cholinesterase inhibitors (ChEIs) are regularly used in Alzheimer's disease. Of the three ChEIs approved for dementia, donepezil is among the most prescribed drugs in the United States with nearly 6 million prescriptions in 2020; however, it is classified as a "known risk" QT interval‐prolonging medication (QTPmed). Given this claim is derived from observational data including single case reports, we aimed to evaluate high‐quality literature on the frequency and nature of proarrhythmic major adverse cardiac events (MACE) associated with donepezil. Methods: We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onwards for randomized controlled trials (RCTs) involving patients age ≥18 years comparing donepezil to placebo. The MACE composite included mortality, sudden cardiac death, non‐fatal cardiac arrest, Torsades de pointes, ventricular tachyarrhythmia, seizure or syncope. Random‐effects meta‐analyses were performed with a treatment‐arm continuity correction for single and double zero event studies. Results: Sixty RCTs (n = 12,463) were included. Twenty‐five of 60 trials (n = 5886) investigated participants with Alzheimer's disease and 33 trials monitored electrocardiogram data. The mean follow‐up duration was 31 weeks (SD = 36). Mortality was the most commonly reported MACE (252/331, 75.8% events), the remainder were syncope or seizures, with no arrhythmia events. There was no increased risk of MACE with exposure to donepezil compared to placebo (risk ratio [RR] 1.08, 95% CI 0.88–1.33, I2 = 0%) and this was consistent in the subgroup analysis of trials including participants with cardiovascular morbidities (RR 1.14, 95% CI 0.88–1.47). Subgroup analysis suggested a trend toward more events with donepezil with follow‐up ≥52 weeks (RR: 1.32, 0.98–1.79). Conclusions: This systematic review with meta‐analysis found donepezil may not be arrhythmogenic. Donepezil was not associated with mortality, ventricular arrhythmias, seizure or syncope, although longer durations of therapy need more study. Further research to clarify actual clinical outcomes related to QTPmed is important to inform prescribing practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Design, synthesis, molecular modeling, in vitro evaluation of novel piperidine‐containing hydrazone derivatives as cholinesterase inhibitors.
- Author
-
Tok, Fatih, Baltaş, Nimet, Abas, Burçin İrem, Tatar Yılmaz, Gizem, Kaya, Süleyman, Koçyiğit‐Kaymakçıoğlu, Bedia, and Çevik, Özge
- Subjects
- *
MOLECULAR dynamics , *ALZHEIMER'S disease , *HYDRAZONE derivatives , *MOLECULAR docking , *STRUCTURAL stability , *CHOLINESTERASE inhibitors - Abstract
In an effort to develop new and effective therapeutic agents for Alzheimer's disease, a series of hydrazone derivatives bearing piperidine rings have been designed and synthesized. The chemical structures of the compounds were characterized by various spectroscopic techniques. In vitro antioxidant and cholinesterase activities of the compounds were evaluated. Among the compounds, N12 exhibited the most antioxidant activity in all methods (CUPRAC, FRAP, DPPH, ABTS). In vitro acetylcholinesterase (AChE) activity results of the compounds showed good IC50 values between 14.124 ± 0.084 and 49.680 ± 0.110 µM were obtained (IC50 = 38.842 ± 0.053 µM for Donepezil). Among the compounds, N7 and N6 are much more effective derivatives than the standard compound donepezil with IC50 values of 14.124 ± 0.084 and 17.968 ± 0.072 µM, respectively. In vitro, butyrylcholinesterase (BChE) inhibition values of the compounds were between 13.505 ± 0.025 and 52.230 ± 0.027 μm. Among the compounds, N6 has the highest BChE inhibition with an IC50 value of 13.505 μm in the series. The cytotoxicity and AChE inhibitory activity of the compounds on SH‐SY5Y cell lines were also evaluated. Kinetic studies were also performed to determine the behavior of the compounds as competitive or noncompetitive inhibitors. The binding modes of N6, which was determined to be highly effective according to in vitro analyses, with AChE and BChE were investigated using molecular docking studies, and the stability of the complexes was determined by molecular dynamics simulations. These findings indicated that AChE and BChE enzymes maintained their overall structural stability and compactness during interactions with compound N6. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Use of donepezil for neurocognitive recovery after brain injury in adult and pediatric populations: a scoping review.
- Author
-
Miller, Avery L., Evanson, Nathan K., and Taylor, J. Michael
- Published
- 2024
- Full Text
- View/download PDF
23. Anti-Oxidant and Anti-Inflammatory Properties of Talinum triangulare Methanol Leaf Extract on Cadmium-Induced Cognitive Dysfunction in Male Wistar Rats.
- Author
-
Inwang, Uduak Anthony, Ben, Ezekiel Etim, Uchewa, Obinna Onwe, Nwuzor, Emmanuel Onyi, Nwaji, Azubuike Raphael, and Umoh, Ekementeabasi Aniebo
- Subjects
LABORATORY rats ,REACTIVE oxygen species ,MEMORY loss ,SPATIAL memory ,ACETYLCHOLINESTERASE - Abstract
Objective; Oxidative stress results in neuronal degeneration leading to cognitive decline. Microglia in brain tissue produces reactive oxygen species (ROS), which modulate synaptic communication between neurons. ROS can lead to neuroinflammation, which can cause neurodegeneration and memory loss. Talinum triangulare was investigated for its cognitive, anti-oxidative and anti-inflammatory potentials in male wistar rats. Materials and methods; 25 adult female rats weighing between 150 g–200 g were grouped (n = 5) into Group 1 (control group) received 1 mL/kg of distilled water, group 2–5 were administered with 100 mg/kg, 200 mg/kg and 400 mg/kg T. triangulare methanol extract and 2.5 mg/kg donepezil, 100 mg/kg cadmium respectively via oral gavage. The administration lasted for 21 days and neuro behavioural parameters, biochemical and histological analysis of the hippocampus were evaluated. The assessment of spatial learning and memory was evaluated using Classic labyrinth task. Results; There was significantly (p < 0.05) reduced escape time latency and increased time latency in the probe trial in Morris water maze; and reduced time latency in the labyrinth by T. triangulare methanol extract (100, 200 and 400 mg/kg) compared with the control and cadmium treated groups. T. triangulare methanol extract and donepezil significantly (p < 0.05) reduced acetylcholinesterase (AChE), tissue necrosis factor-α (TNF-α), interleukin-6 (IL-6) activities and significantly (p < 0.05) increased gluthathione peroxidase activity (GPx) and catalase (CAT) respectively. Conclusion; These findings revealed that T. triangulare methanol extract enhanced cognitive function and exhibited anti-oxidative and anti-inflammatory potentials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Anti-oxidant activity of coenzyme Q10 against AlCl3/D-galactose in albino rat induced cognitive dysfunctions: Behavioral, biochemical, and BACE-1/GSK-3β alterations.
- Author
-
Nawar, Nagat Fawzy, Beltagy, Doha Mohammad, Mohamed, Tarek Mostafa, Tousson, Ehab Mostafa, and El-Keey, Mai Mahmoud
- Subjects
BRAIN-derived neurotrophic factor ,AMYLOID beta-protein precursor ,ALZHEIMER'S disease ,PTEN protein ,IRON in the body - Abstract
The relationship between amyloid beta (Aβ) and oxidative stress (OS), both prominent factors in Alzheimer's disease-related neural degeneration, is deeply interconnected. The cleavage of the extracellular domain of Amyloid precursor protein (APP) and phosphorylating different substrates, respectively, the β-site amyloid precursor protein cleaving enzyme-1 (BACE-1) and Glycogen synthase kinase-3-beta (GSK-3β) enzymes initiate the synthesis of Aβ, which causes cognitive deficits in AD. This study aimed to explore the protective potential of Coenzyme Q10 (CoQ10). It also sought to uncover any synergistic effects when combined with donepezil, an acetylcholinesterase inhibitor, in treating Alzheimer's disease in male albino rats, focusing on the modulation of the BACE-1/GSK-3β pathway. The experiment involved 70 rats categorized into different groups: control, donepezil alone, CoQ10 alone, AD-model, donepezil co-treatment, CoQ10 co-treatment, and CoQ10 + donepezil combination. Various assessments, such as cholinesterase activity, oxidative stress, serum iron profile, Brain Derived Neurotrophic Factor (BDNF), Tau protein, β-site amyloid precursor protein cleaving enzyme-1 (BACE-1), phosphatase and tensin homolog (Pten), and Glycogen synthase kinase-3-beta (GSK-3β), were conducted on behavioral and biochemical aspects. CoQ10 treatment demonstrated memory improvement, enhanced locomotion, and increased neuronal differentiation, mainly through the inhibition of the dual BACE-1/GSK-3β. These findings were substantiated by histological and immunohistological examinations of the hippocampus. Highlights Alzheimer's disease (AD) led to the alteration of BACE-1/GSK-3β. Coenzyme Q10 (CoQ10) alleviated D-Gal and AlCl
3 -induced passive avoidance memory deficits in rats. CoQ10 counteracts Alzheimer's disease by inhibiting acetylcholine esterase. CoQ10 significantly increases levels of BDNF and diminishes Tau burden. CoQ10 acts as a dual BACE1/GSK3β inhibitor. The combination of CoQ10 treatment and donepezil demonstrated potential as a therapeutic approach. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
25. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023.
- Author
-
Yihan Yang, Sheng Wei, Huan Tian, Jing Cheng, Yue Zhong, Xiaoling Zhong, Dunbing Huang, Cai Jiang, and Xiaohua Ke
- Subjects
DRUG side effects ,AGE differences ,DRUG labeling ,DONEPEZIL ,OLDER patients - Abstract
Background: Donepezil in combination with memantine is a widely used clinical therapy for moderate to severe dementia. However, real-world population data on the long-term safety of donepezil in combination with memantine are incomplete and variable. Therefore, the aim of this study was to analyze the adverse events (AEs) of donepezil in combination with memantine according to US Food and Drug Administration Adverse Event Reporting System (FAERS) data to provide evidence for the safety monitoring of this therapy. Methods: We retrospectively analyzed reports of AEs associated with the combination of donepezil and memantine from 2004 to 2023 extracted from the FAERS database. Whether there was a significant association between donepezil and memantine combination therapy and AEs was assessed using four disproportionality analysis methods, namely, the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker methods. To further investigate potential safety issues, we also analyzed differences and similarities in the time of onset and incidence of AEs stratified by sex and differences and similarities in the incidence of AEs stratified by age. Results: Of the 2,400 adverse drug reaction (ADR) reports in which the combination of donepezil and memantine was the primary suspected drug, most of the affected patients were female (54.96%) and older than 65 years of age (79.08%). We identified 22 different system organ classes covering 100 AEs, including some common AEs such as dizziness and electrocardiogram PR prolongation; fall, pleurothotonus and myoclonus were AEs that were not listed on the drug label. Moreover, we obtained 88 reports of AEs in men and 100 reports of AEs in women; somnolence was a common AE in both men and women and was more common in women, whereas pleurothotonus was a more common AE in men. In addition, we analyzed 12 AEs in patients younger than 18 years, 16 in patients between 18 and 65 years, and 113 in patients older than 65 years. The three age groups had distinctive AEs, but lethargy was the common AE among all age groups. Finally, the median time to AE onset was 19 days in all cases. In both men and women, most AEs occurred within a month of starting donepezil plus memantine, but some continued after a year of treatment. Conclusion: Our study identified potential and new AEs of donepezil in combination with memantine; some of these AEs were the same as in the specification, and some of the AE signals were not shown in the specification. In addition, there were sex and age differences in some of the AEs. Therefore, our findings may provide valuable insights for further studies on the safety of donepezil and memantine combination therapy, which are expected to contribute to the safe use of this therapy in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Sustained Cognitive Improvement in Alzheimer's Disease Patients Following a Precision Medicine Protocol: Case Series.
- Author
-
Bredesen, Dale E., Ross, Mary Kay, and Ross, Stephen
- Subjects
ALZHEIMER'S patients ,MILD cognitive impairment ,CEREBRAL atrophy ,ALZHEIMER'S disease ,MEDICAL protocols ,CEREBRAL amyloid angiopathy - Abstract
Arguably, the most important parameter in treating cognitive decline associated with Alzheimer's disease is the length of time in which improvement, if achieved at all, is sustained. However, monotherapies such as donepezil and memantine are associated with a more rapid decline than no treatment in patients over multi-year follow-ups. Furthermore, anti-amyloid antibody treatment, which at best simply slows decline, is associated with accelerated cerebral atrophy, resulting in earlier dementia-associated brain volumes for those treated at the MCI stage than untreated patients. In contrast, a precision medicine approach, in which the multiple potential drivers of cognitive decline are identified for each patient and then targeted with a personalized protocol (such as ReCODE), has led to documented improvements in patients with cognitive decline, but long-term follow-up (>5 years) has not been reported previously. Therefore, here, we report sustained cognitive improvement, in some cases for over a decade, in patients treated with a precision medicine protocol—something that has not been reported in patients treated with anti-cholinesterase, glutamate receptor inhibitory, anti-amyloid, or other therapeutic methods. These case studies warrant long-term cohort studies to determine how frequently such sustained cognitive improvements occur in patients treated with precision medicine protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Neuroprotective Effect of Famotidine in Mouse Models of Alzheimer's Disease.
- Author
-
Sadiq, Mariam H. and Al-Zubaidy, Adeeb A.
- Subjects
H2 receptor antagonists ,ALZHEIMER'S disease ,MICE ,FAMOTIDINE ,LABORATORY mice ,ANIMAL disease models ,ANTIHISTAMINES - Abstract
Background: Famotidine is a competitive histamine H-receptor antagonist that reduces the formation of stomach acid and is used to treat gastrointestinal disorders associated with acid reflux, gastroesophageal reflux disease, duodenal ulcer, gastric ulcer, and pathological hypersecretory disorders. This study is designed to investigate the possible neuroprotective effects of the ranolazine scopolamine-induced Alzheimer's disease-like feature in a mouse model. Methods: Mice were divided equally into five groups (ten mice per group), including control group and induction group. The mice in the induction group were administered scopolamine 1 mg/kg i.p., once daily for 7 days, to induce features similar to Alzheimer's disease. The mice in the remaining three treatment groups were given tested medications prophylactically for 14 days. After that the induction was carried out with scopolamine 1 mg/kg i.p., once daily, while the tested medication dosages were continued for an additional 7 days. These treatment groups included: the donepezil group (5 mg/kg/day), the famotidine group (40 mg/kg/day) and the combined group with donepezil (5 mg/kg/day) and famotidine (40 mg/kg/day); all were administrated i.p., once daily. Behavioral parameters were assessed, among others with the Y-maze test and novel object recognition test, and the inflammatory cytokines and oxidative stress parameters were assessed as well. Results: Famotidine exhibits significant improvements in behavior and memory, level of oxidative stress parameter, and inflammatory cytokines. Conclusions: Famotidine and its combination at prescribed doses in the current study improved learning and memory impairments in mice model of Alzheimer's disease probably via their antioxidant and anti-inflammatory properties confirmed by a significant increase in antioxidant mediator and a significant decrease in oxidative stress marker and inflammatory cytokines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Exploring the most promising anti ‐ Depressant drug targeting Microtubule Affinity Receptor Kinase 4 involved in Alzheimer's Disease through molecular docking and molecular dynamics simulation.
- Author
-
Ahmad, S. Rehan, Zeyaullah, Md., AlShahrani, Abdullah M., Khan, Mohammad Suhail, Muzammil, Khursheed, Ahmed, Faheem, Dawria, Adam, Mohieldin, Ali, Ali, Haroon, and Altijani, Abdelrhman A. G.
- Subjects
- *
MOLECULAR dynamics , *ALZHEIMER'S disease , *MOLECULAR docking , *TARGETED drug delivery , *DONEPEZIL , *MICROTUBULES , *ANTIDEPRESSANTS - Abstract
Alzheimer's Disease (AD) is the prevailing type of neurodegenerative illness, characterised by the accumulation of amyloid beta plaques. The symptoms associated with AD are memory loss, emotional variability, and a decline in cognitive functioning. To date, the pharmaceuticals currently accessible in the marketplace are limited to symptom management. According to several research, antidepressants have demonstrated potential efficacy in the management of AD. In this particular investigation, a total of 24 anti-depressant medications were selected as ligands, while the Microtubule Affinity Receptor Kinase 4 (MARK4) protein was chosen as the focal point of our study. The selection of MARK4 was based on its known involvement in the advancement of AD and other types of malignancies, rendering it a highly prospective target for therapeutic interventions. The initial step involved doing ADMET analysis, which was subsequently followed by molecular docking of 24 drugs. This was succeeded by molecular dynamics simulation and molecular mechanics generalised Born surface area (MMGBSA) calculations. Upon conducting molecular docking experiments, it has been determined that the binding affinities observed fall within the range of -5.5 kcal/mol to -9.0 kcal/mol. In this study, we selected six anti-depressant compounds (CID ID ‐ 4184, 2771, 4205, 5533, 4543, and 2160) based on their binding affinities, which were determined to be -9.0, -8.7, -8.4, -8.3, -8.2, and -8.2, respectively. Molecular dynamics simulations were conducted for all six drugs, with donepezil serving as the control drug. Various analyses were performed, including basic analysis and post-trajectory analysis such as free energy landscape (FEL), polarizable continuum model (PCM), and MMGBSA calculations. Based on the findings from molecular dynamics simulations and the MMGBSA analysis, it can be inferred that citalopram and mirtazapine exhibit considerable potential as anti-depressant agents. Consequently, these compounds warrant further investigation through in vitro and in vivo investigations in the context of treating AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Molecular mechanisms and therapeutic potential of lithium in Alzheimer’s disease: repurposing an old class of drugs.
- Author
-
Yanxin Shen, Meng Zhao, Panpan Zhao, Lingjie Meng, Yan Zhang, Guimei Zhang, Yezi Taishi, and Li Sun
- Subjects
ALZHEIMER'S disease ,LITHIUM carbonate ,DONEPEZIL ,LITHIUM ,DEVELOPMENTAL neurobiology ,NEUROPROTECTIVE agents ,MOOD stabilizers ,GLYCOGEN synthase kinase-3 - Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Despite advances in understanding the pathophysiological mechanisms of AD, effective treatments remain scarce. Lithium salts, recognized as mood stabilizers in bipolar disorder, have been extensively studied for their neuroprotective effects. Several studies indicate that lithium may be a disease-modifying agent in the treatment of AD. Lithium’s neuroprotective properties in AD by acting on multiple neuropathological targets, such as reducing amyloid deposition and tau phosphorylation, enhancing autophagy, neurogenesis, and synaptic plasticity, regulating cholinergic and glucose metabolism, inhibiting neuroinflammation, oxidative stress, and apoptosis, while preserving mitochondrial function. Clinical trials have demonstrated that lithium therapy can improve cognitive function in patients with AD. In particular, meta-analyses have shown that lithium may be a more effective and safer treatment than the recently FDA-approved aducanumab for improving cognitive function in patients with AD. The affordability and therapeutic efficacy of lithium have prompted a reassessment of its use. However, the use of lithium may lead to potential side effects and safety issues, which may limit its clinical application. Currently, several new lithium formulations are undergoing clinical trials to improve safety and efficacy. This review focuses on lithium’s mechanism of action in treating AD, highlighting the latest advances in preclinical studies and clinical trials. It also explores the side effects of lithium therapy and coping strategies, offering a potential therapeutic strategy for patients with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Saponin components in Polygala tenuifolia as potential candidate drugs for treating dementia.
- Author
-
Songzhe Li, Zhitao Hou, Ting Ye, Xiaochen Song, Xinying Hu, and Jing Chen
- Subjects
SAPONINS ,DEMENTIA ,ALZHEIMER'S disease ,VASCULAR dementia ,PARKINSON'S disease ,TREATMENT effectiveness ,DONEPEZIL - Abstract
Objective: This study aims to elucidate the intervention effects of saponin components from Polygala tenuifolia Willd (Polygalaceae) on dementia, providing experimental evidence and new insights for the research and application of saponins in the field of dementia. Materials and Methods: This review is based on a search of the PubMed, NCBI, and Google Scholar databases from their inception to 13 May 2024, using terms such as "P. tenuifolia," "P. tenuifolia and saponins," "toxicity," "dementia," "Alzheimer's disease," "Parkinson's disease dementia," and "vascular dementia." The article summarizes the saponin components of P. tenuifolia, including tenuigenin, tenuifolin, polygalasaponins XXXII, and onjisaponin B, as well as the pathophysiological mechanisms of dementia. Importantly, it highlights the potential mechanisms by which the active components of P. tenuifolia prevent and treat diseases and relevant clinical studies. Results: The saponin components of P. tenuifolia can reduce β-amyloid accumulation, exhibit antioxidant effects, regulate neurotransmitters, improve synaptic function, possess anti-inflammatory properties, inhibit neuronal apoptosis, and modulate autophagy. Therefore, P. tenuifolia may play a role in the prevention and treatment of dementia. Conclusion: The saponin components of P. tenuifolia have shown certain therapeutic effects on dementia. They can prevent and treat dementia through various mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Efficacy and safety of ginkgo biloba extract combined with donepezil hydrochloride in the treatment of Chinese patients with vascular dementia: A systematic review meta-analysis.
- Author
-
Liangyi Xiao, Jie Tang, Huizhong Tan, Yao Xie, Shiliang Wang, Le Xie, and Dahua Wu
- Subjects
GINKGO ,VASCULAR dementia ,CHINESE people ,DONEPEZIL ,BLOOD viscosity ,MINI-Mental State Examination - Abstract
Objective: To conduct a meta-analysis of the effectiveness and safety of ginkgo biloba extract combined with donepezil hydrochloride vs. donepezil for the treatment of vascular dementia (VaD). Methods: Four English databases (PubMed, EMBASE, Web of Science, Cochrane Library) and four Chinese databases [the China National Knowledge Infrastructure Wanfang DATA, the Chongqing VIP Database (VIP), China Biomedical Database (CBM)] were manually searched for literature published from dates of the inception of the databases to September 2023. The randomized controlled trials (RCTs) of ginkgo biloba extract with donepezil hydrochloride vs. donepezil for the treatment of VaD were included. Relevant literature was screened, and the data in the included studies were extracted for quality assessment according to the Risk of bias tool. Results: A total of 1,309 participants were enrolled in the 15 RCTs. Of these, 656 participants were in the experimental group (ginkgo biloba extract combined with donepezil) and 653 participants were in the control group (donepezil). The results showed that combination therapy was superior to donepezil alone, and there were statistically significant differences in several outcomes including RR in change for total effective rate (1.28, 95% confidence intervals 1.20, 1.38, p < 0.001), MD in change for Mini-Mental State Examination score (2.98, 95%CI 2.31, 3.65, p < 0.001), Barthel Index score (8.55,95%CI 1.11, 15.99, p = 0.024), Activity of Daily Living Scale (ADL)score (10.11,95% CI 7.16,13.07, p < 0.001). Conclusion: Ginkgo biloba extract combined with donepezil dramatically improved the total effective rate, MMSE, BI and ADL scores, and decreased homocysteine (HCY), plasma viscosity (PV), whole blood viscosity at high cut (BVH) and whole blood viscosity at low cut (BVL) in VaD patients, while the effect on mean flow velocity and pulse index (PI) of middle cerebral artery (MCA) is not obvious. However, more relevant high-quality RCTs are needed to validate these results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice.
- Author
-
Saruwatari, Junji, Kaneko, Tetsuya, Murata, Tsukasa, Narise, Haruka, Kugimoto, Sawa, Nishimura, Eri, Tetsuka, Natsuki, Ando, Misaki, Oi, Momo, Ota, Masako, Hamada, Nayumi, Kaneda, Keiichiro, Furusho, Shiro, Sakamoto, Masakatsu, Kajiwara‐Morita, Ayami, Oda, Kazutaka, Oniki, Kentaro, Ueda, Keishi, Jono, Hirofumi, and Yasui‐Furukori, Norio
- Subjects
- *
DONEPEZIL , *LIQUID chromatography-mass spectrometry , *RISPERIDONE , *HERBAL medicine ,JAPANESE herbal medicine - Abstract
Aim Methods Results Conclusions Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of donepezil, risperidone, and the major metabolites of both drugs in a real‐world clinical setting.A non‐randomized, open‐label, single‐arm study examining drug–drug interactions was conducted. Fifteen dementia patients taking donepezil for at least 4 weeks and eight schizophrenia patients taking risperidone for at least 2 weeks were orally administered 2.5 g of yokukansan three times a day before or between meals, and blood samples were collected before and 8 weeks after starting co‐treatment with yokukansan. Plasma concentrations of donepezil, risperidone, and each metabolite were measured using high‐performance liquid chromatography–tandem mass spectrometry and compared before and after the 8‐week administration of yokukansan.The plasma concentrations of donepezil and its metabolites (6‐O‐desmethyl‐donepezil, 5‐O‐desmethyl‐donepezil, and donepezil‐N‐oxide), risperidone, and its metabolite paliperidone did not differ before and after the 8‐week treatment with yokukansan.The findings of this study show that the concomitant use of yokukansan may have little clinical impact on the steady‐state blood levels of donepezil and risperidone in patients with dementia or schizophrenia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Donepezil promotes skin flap survival through activation of the HIF‐1α/VEGF signalling pathway.
- Author
-
Lin, Hang, Wang, Kaitao, Yang, Jialong, Wang, An, Deng, Jiapeng, and Lin, Dingsheng
- Subjects
- *
DONEPEZIL , *SKIN grafting , *VASCULAR endothelial growth factors , *PROTEINS , *GRAFT survival , *AUTOPHAGY , *PHENOMENOLOGICAL biology , *RESEARCH funding , *STATISTICAL sampling , *APOPTOSIS , *CELLULAR signal transduction , *DESCRIPTIVE statistics , *BIOCHEMISTRY , *SURGICAL flaps , *MICE , *ANIMAL experimentation , *TISSUE viability , *HEALTH promotion , *POSTOPERATIVE period , *MOLECULAR biology , *NEOVASCULARIZATION , *INTERLEUKINS , *PHARMACODYNAMICS - Abstract
Flaps are mainly used to repair wounds in the clinical setting but can sometimes experience ischaemic necrosis postoperatively. This study investigated whether donepezil, an acetylcholinesterase inhibitor, can enhance the survival rate of flaps. We randomly allocated 36 rats into control, low‐dose (3 mg/kg/day), and high‐dose (5 mg/kg/day) groups. On Postoperative day 7, we assessed flap viability and calculated the mean area of viable flap. After euthanizing the rats, we employed immunological and molecular biology techniques to examine the changes in flap tissue vascularization, apoptosis, autophagy, and inflammation. Donepezil enhanced the expression of hypoxia‐inducible factor and vascular endothelial growth factor to facilitate angiogenesis. In addition, it elevated the expression of LC3B, p62, and beclin to stimulate autophagy. Furthermore, it increased the expression of Bcl‐2 while reducing the expression of Bax, thus inhibiting apoptosis. Finally, it had anti‐inflammatory effects by reducing the levels of IL‐1β, IL‐6, and TNF‐α. The results suggest that donepezil can enhance the viability of randomly generated skin flaps by upregulating HIF‐1α/VEGF signalling pathway, facilitating vascularization, inducing autophagy, suppressing cell apoptosis, and mitigating inflammation within the flap tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Nose-to-Brain Targeted Delivery of Donepezil Hydrochloride via Novel Hyaluronic Acid-Doped Nanotransfersomes for Alzheimer's Disease Mitigation.
- Author
-
Salem, Heba F., Aboud, Heba M., Abdellatif, Mostafa M., and Abou-Taleb, Heba A.
- Subjects
- *
ALZHEIMER'S disease , *INTRANASAL administration , *DONEPEZIL , *NASAL mucosa , *TARGETED drug delivery , *NEURODEGENERATION - Abstract
Alzheimer's disease is the most serious neurodegenerative disorder characterized by cognitive and memorial defects alongside deterioration in behavioral, thinking and social skills. Donepezil hydrochloride (DPZ) is one of the current two FDA-approved cholinesterase inhibitors used for the management of Alzheimer's disease. The current study aimed to formulate hyaluronic acid-coated transfersomes containing DPZ (DPZ-HA-TFS) for brain delivery through the intranasal pathway to surpass its oral-correlated GIT side effects. DPZ-HA-TFS were produced using a thin film hydration method and optimized with a 24 factorial design. The influence of formulation parameters on vesicle diameter, entrapment, cumulative release after 8 h, and ex vivo nasal diffusion after 24 h was studied. The optimal formulation was then evaluated for morphology, stability, histopathology and in vivo biodistribution studies. The optimized DPZ-HA-TFS formulation elicited an acceptable vesicle size (227.5 nm) with 75.83% entrapment efficiency, 37.94% cumulative release after 8 h, 547.49 µg/cm2 permeated through nasal mucosa after 24 h and adequate stability. Histopathological analysis revealed that the formulated DPZ-HA-TFS was nontoxic and tolerable for intranasal delivery. Intranasally administered DPZ-HA-TFS manifested significantly superior values for drug targeting index (5.08), drug targeting efficiency (508.25%) and direct nose-to-brain transport percentage (80.32%). DPZ-HA-TFS might be deemed as a promising intranasal nano-cargo for DPZ cerebral delivery to tackle Alzheimer's disease safely, steadily and in a non-invasive long-term pattern. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Therapeutic Effect of Donepezil on Neuroinflammation and Cognitive Impairment after Moderate Traumatic Brain Injury.
- Author
-
Youn, Dong Hyuk, Lee, Younghyurk, Han, Sung Woo, Kim, Jong-Tae, Jung, Harry, Han, Gui Seung, Yoon, Jung In, Lee, Jae Jun, and Jeon, Jin Pyeong
- Subjects
- *
TREATMENT effectiveness , *BRAIN injuries , *REACTIVE oxygen species , *MICROTUBULE-associated proteins , *BAX protein - Abstract
Background: Despite the important clinical issue of cognitive impairment after moderate traumatic brain injury (TBI), there is currently no suitable treatment. Here, we used in vitro and in vivo models to investigate the effect of Donepezil—an acetylcholinesterase (AChE) inhibitor—on cognitive impairment in the acute period following injury, while focusing on neuroinflammation and autophagy- and mitophagy-related markers. Methods: The purpose of the in vitro study was to investigate potential neuroprotective effects in TBI-induced cells after donepezil treatment, and the in vivo study, the purpose was to investigate therapeutic effects on cognitive impairment in the acute period after injury by analyzing neuroinflammation and autophagy- and mitophagy-related markers. The in vitro TBI model involved injuring SH-SY5Y cells using a cell-injury controller and then investigating the effect of donepezil at a concentration of 80 μM. The in vivo TBI model was made using a stereotaxic impactor for male C57BL/6J mice. Immuno-histochemical markers and cognitive functions were compared after 7 days of donepezil treatment (1 mg/kg/day). Mice were divided into four groups: sham operation with saline treatment, sham operation with donepezil treatment, TBI with saline treatment, and TBI with donepezil treatment (18 mice in each group). Donepezil treatment was administered within 4 h post-TBI. Results: In vitro, donepezil was found to lead to increased cell viability and 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-dazolylcarbocyanine iodide (JC-1), along with decreased reactive oxygen species (ROS), lactate-dehydrogenase (LDH), 2′-7′-dichlorodihydrofluorescein diacetate (DCFH-DA)-positive cells, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells. The mRNA and protein expressions of neuroinflammation (Cyclooxygenase-2, COX-2; NOD-like receptor protein 3, NLRP3; Caspase-1; and Interleukin-1 beta, IL-1β), as well as autophagy- and mitophagy-related markers (death-associated protein kinase 1, DAPK1; PTEN-induced kinase 1, PINK1; BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like, BNIP3L; Beclin-1, BECN1; BCL2-associated X protein, BAX; microtubule-associated protein 1A/1B-light chain 3B (LC3B); Sequestosome-1; and p62) were all found to decrease after donepezil treatment. The in vivo study also showed that donepezil treatment resulted in decreased levels of cortical tissue losses and brain swelling in TBI compared to the TBI group without donepezil treatment. Donepezil treatment was also shown to decrease the mRNA and Western blotting expressions of all markers, and especially COX-2 and BNIP3L, which showed the most significant decreases. Moreover, TBI mice showed an decreased escape latency, increased alteration rate, and improved preference index, altogether pointing to better cognitive performance after donepezil treatment. Conclusions: Donepezil treatment may be beneficial in improving cognitive impairment in the early phase of moderate traumatic brain injury by ameliorating neuroinflammation, as well as autophagy and mitophagy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Recent advances in the total synthesis of galantamine, a natural medicine for Alzheimer's disease.
- Author
-
Cheng, Bichu, Wang, Qi, An, Yi, and Chen, Fener
- Subjects
- *
ALZHEIMER'S disease , *GALANTHAMINE , *NATURAL products , *CHEMICAL synthesis , *DONEPEZIL - Abstract
Covering: 2006 to 2023 (−)-Galantamine is a natural product with distinctive structural features and potent inhibitory activity against acetylcholine esterase (AChE). It is clinically approved for the treatment of Alzheimer's disease. The clinical significance and scarcity of this natural product have prompted extensive and ongoing efforts towards the chemical synthesis of this challenging tetracyclic structure. The objective of this review is to summarize and discuss recent progress in the total synthesis of galantamine from 2006 to 2023. The contents are organized according to the synthetic strategies for the construction of the quaternary center. Key features of each synthesis have been highlighted, followed by a summary and outlook at the end. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Investigating the impact of environmental enrichment on proteome and neurotransmitter‐related profiles in an animal model of Alzheimer's disease.
- Author
-
Nam, Yunkwon, Kim, Sujin, Park, Yong Ho, Kim, Byeong‐Hyeon, Shin, Soo Jung, Leem, Seol Hwa, Park, Hyun Ha, Jung, Gukhwa, Lee, Jeongbeen, Kim, Hyung‐Gun, Yoo, Doo‐Han, Kim, Hak Su, and Moon, Minho
- Subjects
- *
ENVIRONMENTAL enrichment , *ALZHEIMER'S disease , *TANDEM mass spectrometry , *DONEPEZIL , *LIQUID chromatography-mass spectrometry , *SEROTONIN , *ANIMAL models in research , *FRONTAL lobe - Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder associated with behavioral and cognitive impairments. Unfortunately, the drugs the Food and Drug Administration currently approved for AD have shown low effectiveness in delaying the progression of the disease. The focus has shifted to non‐pharmacological interventions (NPIs) because of the challenges associated with pharmacological treatments for AD. One such intervention is environmental enrichment (EE), which has been reported to restore cognitive decline associated with AD effectively. However, the therapeutic mechanisms by which EE improves symptoms associated with AD remain unclear. Therefore, this study aimed to reveal the mechanisms underlying the alleviating effects of EE on AD symptoms using histological, proteomic, and neurotransmitter‐related analyses. Wild‐type (WT) and 5XFAD mice were maintained in standard housing or EE conditions for 4 weeks. First, we confirmed the mitigating effects of EE on cognitive impairment in an AD animal model. Then, histological analysis revealed that EE reduced Aβ accumulation, neuroinflammation, neuronal death, and synaptic loss in the AD brain. Moreover, proteomic analysis by liquid chromatography–tandem mass spectrometry showed that EE enhanced synapse‐ and neurotransmitter‐related networks and upregulated synapse‐ and neurotransmitter‐related proteins in the AD brain. Furthermore, neurotransmitter‐related analyses showed an increase in acetylcholine and serotonin concentrations as well as a decrease in polyamine concentration in the frontal cortex and hippocampus of 5XFAD mice raised under EE conditions. Our findings demonstrate that EE restores cognitive impairment by alleviating AD pathology and regulating synapse‐related proteins and neurotransmitters. Our study provided neurological evidence for the application of NPIs in treating AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Multi-target drugs for Alzheimer's disease.
- Author
-
Turgutalp, Bengisu and Kizil, Caghan
- Subjects
- *
ALZHEIMER'S disease , *ANTIRHEUMATIC agents , *TREATMENT effectiveness , *DONEPEZIL - Abstract
Designed multi-target ligands (DMLs) that target multiple pathologies represent an emerging strategy in Alzheimer's disease (AD) research. DMLs are conceptualized to improve upon single-target therapies by potentially modifying multiple aspects of AD pathophysiology concurrently, a novel approach that reflects our evolving understanding of the disease. Innovations in genetic research and pharmacological development underpin the design of new multi-target drugs (MTDs) with the aim of achieving synergistic effects across various pathological processes implicated in AD. The complexities inherent in MTD design and development, such as optimizing target affinity, highlight the pressing need for continued innovation and collaboration across scientific disciplines. Alzheimer's disease (AD), a leading cause of dementia, increasingly challenges our healthcare systems and society. Traditional therapies aimed at single targets have fallen short owing to the complex, multifactorial nature of AD that necessitates simultaneous targeting of various disease mechanisms for clinical success. Therefore, targeting multiple pathologies at the same time could provide a synergistic therapeutic effect. The identification of new disease targets beyond the classical hallmarks of AD offers a fertile ground for the design of new multi-target drugs (MTDs), and building on existing compounds have the potential to yield in successful disease modifying therapies. This review discusses the evolving landscape of MTDs, focusing on their potential as AD therapeutics. Analysis of past and current trials of compounds with multi-target activity underscores the capacity of MTDs to offer synergistic therapeutic effects, and the flourishing genetic understanding of AD will inform and inspire the development of MTD-based AD therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Evaluation of lipophilicity and drug‐likeness of donepezil‐like compounds using reversed‐phase thin‐layer chromatography.
- Author
-
Šegan, Sandra, Krunić, Mihajlo J., Andrić, Deana B., Šukalović, Vladimir B., Penjišević, Jelena Z., and Jevtić, Ivana I.
- Abstract
Fourteen donepezil‐like acetylcholinesterase (AChE) inhibitors from our library were analyzed using reversed‐phase thin‐layer chromatography to assess their lipophilicity and blood–brain barrier permeability. Compounds possessed N‐benzylpiperidine and N,N‐diarylpiperazine moieties connected via a short carboxamide or amine linker. Retention parameters RM0, b, and C0 were considered as the measures of lipophilicity. Besides, logD of the investigated compounds was determined chromatographically using standard compounds with known logPow and logD values at pH 11. Experimentally obtained lipophilicity parameters correlated well with in silico generated results, and the effect of the nature of the linker between two pharmacophores and substituents on the arylpiperazine part of the molecule was observed. As a result of drug‐likeness analysis, both Lipinski's rule of five and Veber's rule parameters were determined, suggesting that examined compounds could be potential candidates for further drug development. Principal component analysis was performed to obtain an insight into a grouping of compounds based on calculated structural descriptors, experimentally obtained values of lipophilicity, and AChE inhibitory activity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Cognitive Enhancers and Treatments for Alzheimer’s Disease
- Author
-
Devanand, D. P., Fremont, R., Kanba, Shigenobu, Section editor, El-Mallakh, Rif S., Section editor, Zohar, Joseph, Section editor, Krystal, Andrew D., Section editor, Tasman, Allan, editor, Riba, Michelle B., editor, Alarcón, Renato D., editor, Alfonso, César A., editor, Kanba, Shigenobu, editor, Lecic-Tosevski, Dusica, editor, Ndetei, David M., editor, Ng, Chee H., editor, and Schulze, Thomas G., editor
- Published
- 2024
- Full Text
- View/download PDF
41. Cardiovascular Effects of Acetylcholinesterase Inhibitors
- Author
-
Stojiljković, Miloš P., Škrbić, Ranko, Maksimović, Žana M., Dhalla, Naranjan S., Series Editor, Bolli, Roberto, Editorial Board Member, Goyal, Ramesh, Editorial Board Member, Kartha, Chandrasekharan, Editorial Board Member, Kirshenbaum, Lorrie, Editorial Board Member, Makino, Naoki, Editorial Board Member, Mehta, Jawahar L. L., Editorial Board Member, Ostadal, Bohuslav, Editorial Board Member, Pierce, Grant N., Editorial Board Member, Slezak, Jan, Editorial Board Member, Varro, Andras, Editorial Board Member, Werdan, Karl, Editorial Board Member, Weglicki, William B., Editorial Board Member, Djuric, Dragan M., editor, and Agrawal, Devendra K., editor
- Published
- 2024
- Full Text
- View/download PDF
42. Major Neurocognitive Disorders Due to Alzheimer’s Disease
- Author
-
Joshi, Pallavi, Patel, Nisha, Gopalakrishna, Ganesh, Tampi, Rajesh R., editor, and Tampi, Deena J., editor
- Published
- 2024
- Full Text
- View/download PDF
43. Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
- Author
-
Shanghai Mental Health Center and Huashan Hospital
- Published
- 2023
44. Donepezil Versus Non-drug Treatment in Alzheimer's Disease. (CHOLINE-2)
- Author
-
France Alzheimer
- Published
- 2023
45. Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)
- Author
-
Yale University and National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Published
- 2023
46. The Effect of Donepezil on Glycemic Control in Type II Diabetics
- Author
-
Stephen Wills, Principal Investigator
- Published
- 2023
47. Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
- Published
- 2023
48. Liposomal Formulations of Anti-Alzheimer Drugs and siRNA for Nose-to-Brain Delivery: Design, Safety and Efficacy In Vitro.
- Author
-
Lee, David, Shen, Andrew M, Garbuzenko, Olga B, and Minko, Tamara
- Abstract
β-site amyloid precursor protein cleaving enzyme (BACE1) represents a key target for Alzheimer's disease (AD) therapy because it is essential for producing the toxic amyloid β (Aβ) peptide that plays a crucial role in the disease's development. BACE1 inhibitors are a promising approach to reducing Aβ levels in the brain and preventing AD progression. However, systemic delivery of such inhibitors to the brain demonstrates limited efficacy because of the presence of the blood-brain barrier (BBB). Nose-to-brain (NtB) delivery has the potential to overcome this obstacle. Liposomal drug delivery systems offer several advantages over traditional methods for delivering drugs and nucleic acids from the nose to the brain. The current study aims to prepare, characterize, and evaluate in vitro liposomal forms of donepezil, memantine, BACE-1 siRNA, and their combination for possible treatment of AD via NtB delivery. All the liposomal formulations were prepared using the rotary evaporation method. Their cellular internalization, cytotoxicity, and the suppression of beta-amyloid plaque and other pro-inflammatory cytokine expressions were studied. The Calu-3 Transwell model was used as an in vitro system for mimicking the anatomical and physiological conditions of the nasal epithelium and studying the suitability of the proposed formulations for possible NtB delivery. The investigation results show that liposomes provided the effective intracellular delivery of therapeutics, the potential to overcome tight junctions in BBB, reduced beta-amyloid plaque accumulation and pro-inflammatory cytokine expression, supporting the therapeutic potential of our approach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer’s Disease Continuum
- Author
-
Sun H, Lv C, Zhang X, Sun X, Chen S, Li K, Hu Y, Feng Y, Yin T, and Jia J
- Subjects
alzheimer’s disease ,pharmacogenomics ,variant ,gene ,donepezil ,Geriatrics ,RC952-954.6 - Abstract
Hongmei Sun,1,2 Chao Lv,2,3 Xiaoxue Zhang,1,2 Xuan Sun,1,3,4 Siyu Chen,1,3,4 Ke Li,3,4 Yazhuo Hu,2,3 Yuxin Feng,1,2 Tong Yin,2,3 Jianjun Jia2,3 1Medical School, Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Institute of Geriatrics, Chinese PLA General Hospital, Beijing, People’s Republic of China; 3National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing, People’s Republic of China; 4Department of Geriatric Neurology, the Second Medical Centre, Chinese PLA General Hospital, Beijing, People’s Republic of ChinaCorrespondence: Jianjun Jia; Tong Yin, Institute of Geriatrics, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, Haidian District, 100853, People’s Republic of China, Email jiajianjun301@126.com; yintong301@163.comBackground: Genetic variation plays an important role in drug response, there are few relevant studies on patients with Alzheimer’s disease continuum (ADC).Objective: This study focused on the associations between two single nucleotide polymorphisms (SNPs) (rs3793790 and rs2177370) located in the CHAT gene and donepezil response in ADC patients, and further evaluated the associations between the two SNPs and ADC.Material and Methods: According to 2018 National Institute on Aging and Alzheimer’s Association (NIA-AA) standard, amyloid β-protein positive (Aβ+) and negative (Aβ-) patients were recruited according to the Aβ-PET/CT standard. rs3793790 and rs2177370 were genotyped in buccal swab samples by using the MassARRAY system. We used the Mini Mental State Examination (MMSE) in Chinese version, caregiver evaluation, and prescribing behavior to assess therapeutic response during the 9-month period. Using logistic regression models, we analyzed the relationship between the two SNPs and donepezil response in 58 Aβ+ patients treated with donepezil alone at the initial diagnosis of ADC. We also explored a probable link between the two SNPs and ADC in 147 Aβ+ and 73 Aβ– patients using a logistic regression analysis.Results: The chance of donepezil response was higher in patients with the G allele of rs3793790 and/or the A allele of rs2177370 than in those without (odds ratio (OR) 6.83, 95% confidence interval (CI): 1.64– 28.49). Additionally, the rs3793790 variant was not associated with ADC, whereas the A allele in rs2177370 increased 1.51-fold the ADC risk (OR 2.51, 95% CI: 1.28– 4.95).Conclusion: The genetic variants of rs3793790 and rs2177370 were associated with the donepezil response, and rs2177370 may have a moderate relationship with the risk of ADC.Keywords: Alzheimer’s disease, pharmacogenomics, variant, gene, donepezil
- Published
- 2024
50. Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer's Disease: Systematic Review.
- Author
-
Bougea, Anastasia, Angelopoulou, Efthalia, Vasilopoulos, Efthimios, Gourzis, Philippos, and Papageorgiou, Sokratis
- Subjects
- *
ALZHEIMER'S disease , *DONEPEZIL , *FLUOXETINE , *COGNITION disorders , *NEUROPLASTICITY , *MEDICAL research - Abstract
Fluoxetine, a commonly prescribed medication for depression, has been studied in Alzheimer's disease (AD) patients for its effectiveness on cognitive symptoms. The aim of this systematic review is to investigate the therapeutic potential of fluoxetine in cognitive decline in AD, focusing on its anti-degenerative mechanisms of action and clinical implications. According to PRISMA, we searched MEDLINE, up to 1 April 2024, for animal and human studies examining the efficacy of fluoxetine with regard to the recovery of cognitive function in AD. Methodological quality was evaluated using the ARRIVE tool for animal AD studies and the Cochrane tool for clinical trials. In total, 22 studies were analyzed (19 animal AD studies and 3 clinical studies). Fluoxetine promoted neurogenesis and enhanced synaptic plasticity in preclinical models of AD, through a decrease in Aβ pathology and increase in BDNF, by activating diverse pathways (such as the DAF-16-mediated, TGF-beta1, ILK-AKT-GSK3beta, and CREB/p-CREB/BDNF). In addition, fluoxetine has anti-inflammatory properties/antioxidant effects via targeting antioxidant Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome. Only three clinical studies showed that fluoxetine ameliorated the cognitive performance of people with AD; however, several methodological issues limited the generalizability of these results. Overall, the high-quality preclinical evidence suggests that fluoxetine may have neuroprotective, antioxidant, and anti-inflammatory effects in AD animal models. While more high-quality clinical research is needed to fully understand the mechanisms underlying these effects, fluoxetine is a promising potential treatment for AD patients. If future clinical trials confirm its anti-degenerative and neuroprotective effects, fluoxetine could offer a new therapeutic approach for slowing down the progression of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.